Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS).

Fabiani E, Calabrese C, Niscola P, Balleari E, Molteni A, Finelli C, Falconi G, Fenu S, Fianchi L, Criscuolo M, Salvi F, Lavorgna S, Buccisano F, Maurillo L, Lo Coco F, Cilloni D, Voso MT.

Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15655. [Epub ahead of print] No abstract available.

PMID:
30407614
2.

Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes.

Falconi G, Fabiani E, Piciocchi A, Criscuolo M, Fianchi L, Lindfors Rossi EL, Finelli C, Cerqui E, Ottone T, Molteni A, Parma M, Santarone S, Candoni A, Sica S, Leone G, Lo-Coco F, Voso MT.

Leukemia. 2019 Mar;33(3):785-790. doi: 10.1038/s41375-018-0284-9. Epub 2018 Oct 5. No abstract available.

PMID:
30291338
3.

Therapy-related myeloid neoplasms: clinical perspectives.

Fianchi L, Criscuolo M, Fabiani E, Falconi G, Maraglino AME, Voso MT, Pagano L.

Onco Targets Ther. 2018 Sep 17;11:5909-5915. doi: 10.2147/OTT.S101333. eCollection 2018. Review.

4.

Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes.

Gurnari C, Latagliata R, Buccisano F, Piciocchi A, Fenu S, Mancini S, Fianchi L, Criscuolo M, Sarlo C, Romano A, Falconi G, Niscola P, Di Veroli A, Breccia M, Piccioni A, Aloe-Spiriti MA, Lo-Coco F, Voso MT; GROM-L (Gruppo Romano-Laziale MDS); GROM-L (Gruppo Romano-Laziale MDS).

Leuk Res. 2018 Aug;71:89-91. doi: 10.1016/j.leukres.2018.07.002. Epub 2018 Jul 10. No abstract available.

PMID:
30029156
5.

Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.

Maurillo L, Buccisano F, Spagnoli A, Voso MT, Fianchi L, Papayannidis C, Gaidano GL, Breccia M, Musto P, De Bellis E, Del Principe MI, Lunghi M, Lessi F, Martinelli G, Venditti A.

Ann Hematol. 2018 Oct;97(10):1767-1774. doi: 10.1007/s00277-018-3374-x. Epub 2018 Jun 10.

PMID:
29947973
6.

Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes.

Efficace F, Cottone F, Abel G, Niscola P, Gaidano G, Bonnetain F, Anota A, Caocci G, Cronin A, Fianchi L, Breccia M, Stauder R, Platzbecker U, Palumbo GA, Luppi M, Invernizzi R, Bergamaschi M, Borin L, Di Tucci AA, Zhang H, Sprangers M, Vignetti M, Mandelli F.

Cancer. 2018 Mar 15;124(6):1251-1259. doi: 10.1002/cncr.31193. Epub 2017 Dec 12.

7.

Role of flow-cytometric immunophenotyping in prediction of BCR/ABL1 gene rearrangement in adult B-cell acute lymphoblastic leukemia.

Corrente F, Bellesi S, Metafuni E, Puggioni PL, Marietti S, Ciminello AM, Za T, Sorà F, Fianchi L, Sica S, De Stefano V, Chiusolo P.

Cytometry B Clin Cytom. 2018 May;94(3):468-476. doi: 10.1002/cyto.b.21605. Epub 2017 Dec 29.

PMID:
29220871
8.

Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome.

Criscuolo M, Fianchi L, Chiusolo P, Giammarco S, Bacigalupo A, Pagano L.

J Clin Immunol. 2018 Jan;38(1):7-9. doi: 10.1007/s10875-017-0467-6. Epub 2017 Dec 1. No abstract available.

PMID:
29196934
9.

A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry.

Mayer F, Faglioni L, Agabiti N, Fenu S, Buccisano F, Latagliata R, Ricci R, Spiriti MAA, Tatarelli C, Breccia M, Cimino G, Fianchi L, Criscuolo M, Gumenyuk S, Mancini S, Maurillo L, Nobile C, Niscola P, Piccioni AL, Tafuri A, Trapè G, Andriani A, De Fabritiis P, Voso MT, Davoli M, Zini G.

Mediterr J Hematol Infect Dis. 2017 Jul 1;9(1):e2017046. doi: 10.4084/MJHID.2017.046. eCollection 2017.

10.

Treatment of Low-Blast Count AML using Hypomethylating Agents.

De Bellis E, Fianchi L, Buccisano F, Criscuolo M, Maurillo L, Cicconi L, Brescini M, Del Principe MI, Di Veroli A, Venditti A, Amadori S, Arcese W, Lo-Coco F, Voso MT.

Mediterr J Hematol Infect Dis. 2017 Jul 1;9(1):e2017045. doi: 10.4084/MJHID.2017.045. eCollection 2017. Review.

11.

ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems.

Buckstein R, Balleari E, Wells R, Santini V, Sanna A, Salvetti C, Crisà E, Allione B, Danise P, Finelli C, Clavio M, Poloni A, Salvi F, Cilloni D, Oliva EN, Musto P, Houston B, Zhu N, Geddes M, Leitch H, Leber B, Sabloff M, Nevill TJ, Yee KW, Storring JM, Francis J, Maurillo L, Latagliata R, Spiriti MAA, Andriani A, Piccioni AL, Fianchi L, Fenu S, Gumenyuk S, Buccisano F.

Am J Hematol. 2017 Oct;92(10):1037-1046. doi: 10.1002/ajh.24842. Epub 2017 Jul 29.

12.

RNA editing signature during myeloid leukemia cell differentiation.

Rossetti C, Picardi E, Ye M, Camilli G, D'Erchia AM, Cucina L, Locatelli F, Fianchi L, Teofili L, Pesole G, Gallo A, Sorrentino R.

Leukemia. 2017 Dec;31(12):2824-2832. doi: 10.1038/leu.2017.134. Epub 2017 May 9.

13.

Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.

Voso MT, Leone G, Piciocchi A, Fianchi L, Santarone S, Candoni A, Criscuolo M, Masciulli A, Cerqui E, Molteni A, Finelli C, Parma M, Poloni A, Carella AM, Spina F, Cortelezzi A, Salvi F, Alessandrino EP, Rambaldi A, Sica S.

Ann Oncol. 2017 Jul 1;28(7):1547-1553. doi: 10.1093/annonc/mdx154.

PMID:
28368509
14.

Clonal evolution in therapy-related neoplasms.

Fabiani E, Falconi G, Fianchi L, Criscuolo M, Ottone T, Cicconi L, Hohaus S, Sica S, Postorino M, Neri A, Lionetti M, Leone G, Lo-Coco F, Voso MT.

Oncotarget. 2017 Feb 14;8(7):12031-12040. doi: 10.18632/oncotarget.14509.

15.

Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality?

Dragonetti G, Criscuolo M, Fianchi L, Pagano L.

Med Mycol. 2017 Jan 1;55(1):82-86. Epub 2016 Dec 2. Review.

PMID:
27915304
16.

Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study.

Tisi MC, Hohaus S, Cuccaro A, Innocenti I, De Carolis E, Za T, D'Alò F, Laurenti L, Fianchi L, Sica S, Sanguinetti M, De Stefano V, Pagano L.

Haematologica. 2017 Mar;102(3):e108-e111. doi: 10.3324/haematol.2016.151837. Epub 2016 Nov 17. No abstract available.

17.

Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey.

Trecarichi EM, Pagano L, Martino B, Candoni A, Di Blasi R, Nadali G, Fianchi L, Delia M, Sica S, Perriello V, Busca A, Aversa F, Fanci R, Melillo L, Lessi F, Del Principe MI, Cattaneo C, Tumbarello M; HaematologicMalignancies Associated Bloodstream Infections Surveillance (HEMABIS) registry - Sorveglianza Epidemiologica Infezioni Funginein Emopatie Maligne(SEIFEM) group, Italy.

Am J Hematol. 2016 Nov;91(11):1076-1081. doi: 10.1002/ajh.24489. Epub 2016 Jul 29.

18.

Common Genetic Polymorphisms within NFκB-Related Genes and the Risk of Developing Invasive Aspergillosis.

Lupiañez CB, Villaescusa MT, Carvalho A, Springer J, Lackner M, Sánchez-Maldonado JM, Canet LM, Cunha C, Segura-Catena J, Alcazar-Fuoli L, Solano C, Fianchi L, Pagano L, Potenza L, Aguado JM, Luppi M, Cuenca-Estrella M, Lass-Flörl C, Einsele H, Vázquez L; PCRAGA Study Group, Ríos-Tamayo R, Loeffler J, Jurado M, Sainz J.

Front Microbiol. 2016 Aug 12;7:1243. doi: 10.3389/fmicb.2016.01243. eCollection 2016.

19.

Dose-Dependent Effect of Granulocyte Transfusions in Hematological Patients with Febrile Neutropenia.

Teofili L, Valentini CG, Di Blasi R, Orlando N, Fianchi L, Zini G, Sica S, De Stefano V, Pagano L.

PLoS One. 2016 Aug 3;11(8):e0159569. doi: 10.1371/journal.pone.0159569. eCollection 2016.

20.

Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study.

Buccisano F, Piccioni AL, Nobile C, Criscuolo M, Niscola P, Tatarelli C, Fianchi L, Villivà N, Neri B, Carmosino I, Gumenyuk S, Mancini S, Voso MT, Maurillo L, Breccia M, Zini G, Venditti A, Fenu S, Spiriti MA, Latagliata R; GROM (Gruppo Romano Mielodisplasie).

Ann Hematol. 2016 Jun;95(7):1059-65. doi: 10.1007/s00277-016-2667-1. Epub 2016 Apr 19.

PMID:
27091349
21.

Polymorphisms in Host Immunity-Modulating Genes and Risk of Invasive Aspergillosis: Results from the AspBIOmics Consortium.

Lupiañez CB, Canet LM, Carvalho A, Alcazar-Fuoli L, Springer J, Lackner M, Segura-Catena J, Comino A, Olmedo C, Ríos R, Fernández-Montoya A, Cuenca-Estrella M, Solano C, López-Nevot MÁ, Cunha C, Oliveira-Coelho A, Villaescusa T, Fianchi L, Aguado JM, Pagano L, López-Fernández E, Potenza L, Luppi M, Lass-Flörl C, Loeffler J, Einsele H, Vazquez L; PCRAGA Study Group, Jurado M, Sainz J.

Infect Immun. 2015 Dec 14;84(3):643-57. doi: 10.1128/IAI.01359-15.

22.

Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency.

Criscuolo M, Fianchi L, Dragonetti G, Pagano L.

Expert Rev Hematol. 2016;9(2):197-208. doi: 10.1586/17474086.2016.1127156. Epub 2016 Jan 8. Review.

PMID:
26629730
23.

Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes.

Falconi G, Fabiani E, Fianchi L, Criscuolo M, Raffaelli CS, Bellesi S, Hohaus S, Voso MT, D'Alò F, Leone G.

Exp Hematol. 2016 Jan;44(1):75-83.e1-4. doi: 10.1016/j.exphem.2015.10.005. Epub 2015 Oct 28.

PMID:
26521017
24.

Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia.

Voso MT, Lo-Coco F, Fianchi L.

Curr Opin Oncol. 2015 Nov;27(6):532-9. doi: 10.1097/CCO.0000000000000231. Review.

PMID:
26352541
25.

Fanconi anemia gene variants in therapy-related myeloid neoplasms.

Voso MT, Fabiani E, Zang Z, Fianchi L, Falconi G, Padella A, Martini M, Li Zhang S, Santangelo R, Larocca LM, Criscuolo M, La Brocca A, Cutcutache I, Rozen S, Simonetti G, Manfrini M, Martinelli G, Hohaus S, Leone G, Tan P, Tenen DG.

Blood Cancer J. 2015 Jul 3;5:e323. doi: 10.1038/bcj.2015.44. No abstract available.

26.

Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.

Voso MT, Niscola P, Piciocchi A, Fianchi L, Maurillo L, Musto P, Pagano L, Mansueto G, Criscuolo M, Aloe-Spiriti MA, Buccisano F, Venditti A, Tendas A, Piccioni AL, Zini G, Latagliata R, Filardi N, Fragasso A, Fenu S, Breccia M; GROM (Gruppo Romano e Laziale MDS) and Basilicata MDS Registry.

Eur J Haematol. 2016 Apr;96(4):344-51. doi: 10.1111/ejh.12595. Epub 2015 Jun 21.

PMID:
26018238
27.

Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias.

Fianchi L, Pagano L, Piciocchi A, Candoni A, Gaidano G, Breccia M, Criscuolo M, Specchia G, Maria Pogliani E, Maurillo L, Aloe-Spiriti MA, Mecucci C, Niscola P, Rossetti E, Mansueto G, Rondoni M, Fozza C, Invernizzi R, Spadea A, Fenu S, Buda G, Gobbi M, Fabiani E, Sica S, Hohaus S, Leone G, Voso MT.

Am J Hematol. 2015 May;90(5):E80-5. doi: 10.1002/ajh.23966. Epub 2015 Mar 3.

28.

Rapid response of nodular CD30-positive mycosis fungoides to brentuximab vedotin.

Criscuolo M, Fianchi L, Voso MT, Pagano L.

Br J Haematol. 2015 Mar;168(5):617. doi: 10.1111/bjh.13220. Epub 2014 Nov 18. No abstract available.

PMID:
25403895
29.

SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms.

Fabiani E, Falconi G, Fianchi L, Criscuolo M, Leone G, Voso MT.

Haematologica. 2014 Sep;99(9):e152-3. doi: 10.3324/haematol.2014.108159. Epub 2014 Jun 6. No abstract available.

30.

Mutational analysis of bone marrow mesenchymal stromal cells in myeloid malignancies.

Fabiani E, Falconi G, Fianchi L, Guidi F, Bellesi S, Voso MT, Leone G, D'Alò F.

Exp Hematol. 2014 Sep;42(9):731-3. doi: 10.1016/j.exphem.2014.04.011. Epub 2014 May 4. No abstract available.

PMID:
24796317
31.

Why methylation is not a marker predictive of response to hypomethylating agents.

Voso MT, Santini V, Fabiani E, Fianchi L, Criscuolo M, Falconi G, Guidi F, Hohaus S, Leone G.

Haematologica. 2014 Apr;99(4):613-9. doi: 10.3324/haematol.2013.099549. Review.

32.

Methylenetetrahydrofolate reductase polymorphisms in myelodysplastic syndromes and therapy-related myeloid neoplasms.

Criscuolo M, Chiusolo P, Giammarco S, Giachelia M, Fianchi L, Fabiani E, Falconi G, Hohaus S, Sica S, Leone G, Voso MT.

Leuk Lymphoma. 2014 Dec;55(12):2942-4. doi: 10.3109/10428194.2014.903475. Epub 2014 Apr 22. No abstract available.

PMID:
24625325
33.

Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile.

Breccia M, Voso MT, Maurillo L, Niscola P, Fianchi L, Aloe Spiriti MA, Buccisano F, Latagliata R, Pelliccia S, Fenu S, Tendas A, Alimena G.

Am J Hematol. 2014 May;89(5):565. doi: 10.1002/ajh.23677. Epub 2014 Feb 28. No abstract available.

34.

The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes.

Fabiani E, Fianchi L, Falconi G, Boncompagni R, Criscuolo M, Guidi F, La Brocca A, Hohaus S, Leone G, Voso MT.

Leuk Lymphoma. 2014 Jul;55(7):1538-43. doi: 10.3109/10428194.2013.845885. Epub 2013 Nov 1.

PMID:
24047476
35.

Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.

Voso MT, Breccia M, Lunghi M, Poloni A, Niscola P, Finelli C, Bari A, Musto P, Zambello R, Fianchi L, Alimena G, Leone G.

Eur J Haematol. 2013 Apr;90(4):345-8. doi: 10.1111/ejh.12079. Epub 2013 Feb 28.

PMID:
23336938
36.

Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine.

Breccia M, Fianchi L, Lunghi M, Gaidano G, Levis A, Finelli C, Santini V, Musto P, Mansueto G, Oliva EN, Leoni P, Spiriti MA, Hohaus S, Leone G, Alimena G, Voso MT.

Leuk Lymphoma. 2013 Aug;54(8):1786-7. doi: 10.3109/10428194.2012.749406. Epub 2012 Dec 10. No abstract available.

PMID:
23151268
37.

Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases.

Voso MT, Fabiani E, Fianchi L, Falconi G, Criscuolo M, Santangelo R, Chiusolo P, Betti S, D'Alo' F, Hohaus S, De Stefano V, Leone G.

Leukemia. 2013 Apr;27(4):982-5. doi: 10.1038/leu.2012.267. Epub 2012 Sep 11. No abstract available.

PMID:
22964944
38.

High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study.

Fianchi L, Criscuolo M, Breccia M, Maurillo L, Salvi F, Musto P, Mansueto G, Gaidano G, Finelli C, Aloe-Spiriti A, Santini V, Greco M, Hohaus S, Leone G, Voso MT.

Leuk Lymphoma. 2013 Mar;54(3):658-61. doi: 10.3109/10428194.2012.719617. Epub 2012 Aug 30. No abstract available.

PMID:
22873829
39.

Outcome of therapy-related myeloid neoplasms treated with azacitidine.

Fianchi L, Criscuolo M, Lunghi M, Gaidano G, Breccia M, Levis A, Finelli C, Santini V, Musto P, Oliva EN, Leoni P, Aloe Spiriti A, D'Alò F, Hohaus S, Pagano L, Leone G, Voso MT.

J Hematol Oncol. 2012 Aug 1;5:44. doi: 10.1186/1756-8722-5-44.

40.

Small lymphocytic lymphoma in a patient with Fabry disease.

Tisi MC, Zampetti A, Feliciani C, Fianchi L, Valentini CG, Hohaus S, Larocca LM, Leone G, Voso MT.

Leuk Lymphoma. 2013 Jan;54(1):184-5. doi: 10.3109/10428194.2012.701294. Epub 2012 Jul 9. No abstract available.

PMID:
22694792
41.

Incidence of acute myeloid leukemia after breast cancer.

Valentini CG, Fianchi L, Voso MT, Caira M, Leone G, Pagano L.

Mediterr J Hematol Infect Dis. 2011;3(1):e2011069. doi: 10.4084/MJHID.2011.069. Epub 2011 Dec 22.

42.

Similarities and differences between therapy-related and elderly acute myeloid leukemia.

D'Alò F, Fianchi L, Fabiani E, Criscuolo M, Greco M, Guidi F, Pagano L, Leone G, Voso MT.

Mediterr J Hematol Infect Dis. 2011;3(1):e2011052. doi: 10.4084/MJHID.2011.052. Epub 2011 Nov 28.

43.

Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome.

Fianchi L, Leone G, Posteraro B, Sanguinetti M, Guidi F, Valentini CG, Voso MT, Pagano L.

Leuk Res. 2012 Mar;36(3):331-3. doi: 10.1016/j.leukres.2011.11.012. Epub 2011 Dec 15.

PMID:
22177732
44.

The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue.

Chiusolo P, Giammarco S, Bellesi S, Metafuni E, Piccirillo N, De Ritis D, Marietti S, Federica S, Laurenti L, Fianchi L, Hohaus S, Giuseppe L, Sica S.

Cancer Chemother Pharmacol. 2012 Mar;69(3):691-6. doi: 10.1007/s00280-011-1751-4. Epub 2011 Oct 9.

PMID:
21984221
45.

Therapy-related myeloid neoplasms.

Leone G, Fianchi L, Voso MT.

Curr Opin Oncol. 2011 Nov;23(6):672-80. doi: 10.1097/CCO.0b013e32834bcc2a. Review.

PMID:
21918440
46.

Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule.

Voso MT, Fianchi L, Criscuolo M, Greco M, D'Alo F, Hohaus S, Pagano L, Leone G.

Leuk Res. 2012 Jan;36(1):e15-7. doi: 10.1016/j.leukres.2011.08.010. Epub 2011 Sep 9. No abstract available.

PMID:
21907408
47.

Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine.

Voso MT, Fabiani E, Piciocchi A, Matteucci C, Brandimarte L, Finelli C, Pogliani E, Angelucci E, Fioritoni G, Musto P, Greco M, Criscuolo M, Fianchi L, Vignetti M, Santini V, Hohaus S, Mecucci C, Leone G.

Leukemia. 2011 Dec;25(12):1910-3. doi: 10.1038/leu.2011.170. Epub 2011 Jul 15. No abstract available.

PMID:
21760590
48.

5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature.

Greco M, Criscuolo M, Fianchi L, Fabiani E, Pagano L, Voso M.

Mediterr J Hematol Infect Dis. 2011;3(1):e2011011. doi: 10.4084/MJHID.2011.011. Epub 2011 Mar 15.

49.

Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B?

Pagano L, Valentini CG, Fianchi L, Caira M.

J Chemother. 2011 Feb;23(1):5-8. Review.

PMID:
21482486
50.

Primary plasma cell leukemia: a retrospective multicenter study of 73 patients.

Pagano L, Valentini CG, De Stefano V, Venditti A, Visani G, Petrucci MT, Candoni A, Specchia G, Visco C, Pogliani EM, Ferrara F, Galieni P, Gozzetti A, Fianchi L, De Muro M, Leone G, Musto P, Pulsoni A; GIMEMA-ALWP (Gruppo Italiano Malattie EMatologiche dell'Adulto, Acute Leukemia Working Party: coordinator Sergio Amadori).

Ann Oncol. 2011 Jul;22(7):1628-35. doi: 10.1093/annonc/mdq646. Epub 2011 Jan 20.

PMID:
21252060

Supplemental Content

Loading ...
Support Center